Lana Pine

Massimo Radin, MD, PhD, explains how tailoring oral therapy in rheumatoid arthritis, via the TuTOR App, can improve medication adherence.

Bristol Myers Squibb announced positive results from a phase 2 trial that evaluated deucravacitinib compared with placebo in patients with moderate-to-severe systemic lupus erythematosus.

“The role of terminally differentiated T effector memory re-expressing Temra in RA pathogenesis and disease activity is still unclear," investigators stated.

Eliseo Pascual, MD, PhD, discusses sex and gender regarding the diagnosis, treatment, and management of rheumatic disease.

Bristol Myers Squibb shares positive phase 2 results evaluating deucravacitinib in patients with moderate-to-severe systemic lupus erythematosus.

Nicola Luigi Bragazzi, MD, PhD, explains the importance of sex-based medicine in psoriatic arthritis and shares his advice for future studies.

Catch up on Rheumatology Network's top articles of May 2022.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 28, 2022.

Look back on Rheumatology Network's Congress of Clinical Rheumatology (CCR) East's conference coverage.

COVID-19 has raised additional concerns for rheumatologists, especially regarding health care for patients with rheumatic diseases.

Investigators conducted a meta-analysis to determine the association between psoriasis and an eventual psoriatic arthritis diagnosis.

Anne Winkler, MD, discusses the importance of patient-reported outcome measures when treating her patients with lupus.

Clinicians give their opinions on patient-reported outcome measures regarding both initial diagnosis and management of patients with rheumatic disease.

James Woody, MD, PhD, explains the benefits of treating Dupuytren’s disease with anti-tumor necrosis factor (TNF).

Janet E McDonagh, MD, FRCP explains the importance of obtaining both the patient and parent perspective in pediatric rheumatology.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 21, 2022.

The Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion to expand Novartis secukinumab indication to enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA).

Benjamin Nowell, PhD, and Stuart Silverman, MD, FACP, FACR, discuss the recently published review of current literature regarding cannabis for rheumatic disease pain.

Zachary S Wallace, MD, explains his approach to diagnosing and managing IgG4-related disease and some of the clinical trials that are on the horizon.

Janet Pope, MD, MPH, explains her treatment strategies for unresponsive patients with rheumatoid arthritis as well as clinical pearls of 2021.

Julie J Paik, MD, MHS, discusses the clinicoserological spectrum of inflammatory myopathy in the context of rheumatic diseases and how autoantibody profiles can help predict myositis phenotype and disease course.

Leonard Calabrese, DO, explains the history of interferon history in rheumatology, immunology for the rheumatologist, and COVID-19 immunology regarding autoimmune and inflammatory manifestations.

Arthur Kavanaugh, MD, discusses his recent CCR East presentations “The Immunopathogenesis of Psoriatic Arthritis and Immunologically Targeted Therapy” and “Hot Topics in Rheumatoid Arthritis.”

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 14, 2022.

Anne Winkler, MD, discusses her upcoming CCR East presentation, “Targeting Lupus Nephritis.”

While genetics are linked to gout diagnosis and lifestyle factors are related to risk, the association between healthy choices and risk mitigation remained unclear.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 7, 2022.

Janet E McDonagh, MD, FRCP, discusses the study “The Role of Age in Delays to Rheumatological Care in Juvenile Idiopathic Arthritis.”

According to investigators, pulmonary hypertension indicates an increased risk of mortality in patients with systemic sclerosis.

The cross-sectional analysis determined cognitive performance of patients with systemic lupus erythematosus was significantly lower when compared with controls in both motor speed and psychomotor speed domains.